Cargando…

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER

Detalles Bibliográficos
Autores principales:	Chien, Kelly, Ong, Faustine, Kim, Kunhwa, LI, Ziyi, Kanagal-Shamanna, Rashmi, Dinardo, Courtney, Takahashi, Koichi, Montalban-Bravo, Guillermo, Hammond, Danielle, Sasaki, Koji, Pierce, Sherry, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429520/ http://dx.doi.org/10.1097/01.HS9.0000976628.14722.19

Ejemplares similares

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study
por: Takahashi, Koichi, et al.
Publicado: (2016)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2019)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
por: Nguyen, Daniel, et al.
Publicado: (2023)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
por: Hsu, Joanne I., et al.
Publicado: (2018)

PB2200: CLONAL HEMATOPOIESIS AT THE CROSSROADS OF INFLAMMATORY BOWEL DISEASES AND HEMATOLOGICAL MALIGNANCIES: A BIOLOGICAL LINK?
por: Cumbo, C., et al.
Publicado: (2022)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

2481. Interactive Dashboards for Improved Tracking and Communication of CLABSI Prevention Efforts
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2023)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
por: Bannon, Sarah A., et al.
Publicado: (2021)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Current Understanding of DDX41 Mutations in Myeloid Neoplasms
por: Kim, Kunhwa, et al.
Publicado: (2023)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Hematopoiesis under telomere attrition at the single-cell resolution
por: Thongon, Natthakan, et al.
Publicado: (2021)

P1330: CYTOREDUCTIVE CHEMOTHERAPY COULD ACCELERATE THE LOSS OF CLONAL DIVERSITY IN HEMATOPOIETIC STEM CELLS AND PROMOTES THE CONVERGENT EVOLUTION OF THERAPY-RELATED CLONAL HEMATOPOIESIS
por: Uryu, Hidetaka, et al.
Publicado: (2023)

Chipping in on clonal hematopoiesis
por: Gillis, Nancy K., et al.
Publicado: (2017)

Evolution of clonal hematopoiesis
por: van Zeventer, Isabelle A., et al.
Publicado: (2023)

PB2204: THE ROLE OF HES6 IN NORMAL HUMAN HEMATOPOIESIS
por: De Vos, T., et al.
Publicado: (2022)

Venetoclax resistance: mechanistic insights and future strategies
por: Ong, Faustine, et al.
Publicado: (2022)

Clonal hematopoiesis in sickle cell disease
por: Liggett, L. Alexander, et al.
Publicado: (2022)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qr64kutp5ljs4j52erl0dn2p4